Short Title: Pharm Last Published:  07/29/22 01:33:17 PM (Central)
Element: Exploration Medical Capability (ExMC)
Evidence:  Report
Risk Master Logic Diagram:  Not Available
Point of Contact:  Kris Lehnhardt
HRP Risk Status: Active [current research ongoing]
Risk Ratings and Dispositions per Design Reference Mission (DRM) Category
DRM CategoriesMission Type and
OperationsLong-Term Health
LxCRisk Disposition *LxCRisk Disposition *
Low Earth OrbitShort
(<30 days)
(30 days-1 year)
Lunar OrbitalShort
(<30 days)
(30 days-1 year)
3x2Accepted with Optimization2x2Accepted with Monitoring
Lunar Orbital
+ Surface
(<30 days)
3x1Accepted with Optimization2x1Accepted with Monitoring
(30 days-1 year)
4x2Accepted with Optimization2x2Accepted with Monitoring
(<1 year)
4x3Requires Characterization3x2Accepted with Monitoring
Mars Planetary
(730-1224 days)
5x3Requires Mitigation5x3Requires Mitigation
Note: LxC is the likelihood and consequence rating. The information above was last approved by the Human System Risk Board in 12/2021.
Risk Statement
Given that there is no current method to sufficiently characterize medication use, drug quality and performance, clinical outcomes, and the impact of a hostile space environment on pharmaceutical stability and potency during long-duration exploration missions, there is a possibility that provision of a safe and effective drug treatment will be significantly limited, impacting crew health and performance.
Gaps (6)